Mengis Capital Management Inc. Sells 2,426 Shares of Agilent Technologies, Inc. (NYSE:A)

Mengis Capital Management Inc. lessened its holdings in shares of Agilent Technologies, Inc. (NYSE:A) by 9.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 24,614 shares of the medical research company’s stock after selling 2,426 shares during the quarter. Mengis Capital Management Inc.’s holdings in Agilent Technologies were worth $3,655,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Livelsberger Financial Advisory purchased a new stake in Agilent Technologies during the third quarter valued at about $28,000. Crewe Advisors LLC raised its holdings in shares of Agilent Technologies by 114.8% during the 2nd quarter. Crewe Advisors LLC now owns 189 shares of the medical research company’s stock valued at $25,000 after buying an additional 101 shares in the last quarter. Ashton Thomas Securities LLC bought a new stake in Agilent Technologies in the 3rd quarter worth approximately $31,000. Ridgewood Investments LLC purchased a new stake in Agilent Technologies in the second quarter worth approximately $29,000. Finally, Fortitude Family Office LLC grew its position in Agilent Technologies by 68.3% during the third quarter. Fortitude Family Office LLC now owns 234 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 95 shares during the last quarter.

Agilent Technologies Stock Performance

Shares of A stock opened at $133.66 on Wednesday. The company has a market cap of $38.40 billion, a PE ratio of 27.73, a PEG ratio of 5.89 and a beta of 1.07. The company has a current ratio of 1.78, a quick ratio of 1.37 and a debt-to-equity ratio of 0.36. The business’s fifty day simple moving average is $139.17 and its 200-day simple moving average is $138.16. Agilent Technologies, Inc. has a 12-month low of $106.96 and a 12-month high of $155.35.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 21st. The medical research company reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.26 by $0.06. The firm had revenue of $1.58 billion during the quarter, compared to analyst estimates of $1.56 billion. Agilent Technologies had a net margin of 21.75% and a return on equity of 25.26%. The business’s quarterly revenue was down 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned $1.43 EPS. Analysts expect that Agilent Technologies, Inc. will post 5.24 earnings per share for the current fiscal year.

Agilent Technologies Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, October 23rd. Stockholders of record on Tuesday, October 1st were given a dividend of $0.236 per share. The ex-dividend date of this dividend was Tuesday, October 1st. This represents a $0.94 annualized dividend and a dividend yield of 0.71%. Agilent Technologies’s payout ratio is 19.50%.

Analyst Ratings Changes

A has been the topic of several analyst reports. TD Cowen lifted their price objective on Agilent Technologies from $153.00 to $160.00 and gave the stock a “buy” rating in a report on Thursday, August 22nd. Bank of America lifted their price target on Agilent Technologies from $140.00 to $147.00 and gave the stock a “neutral” rating in a research note on Thursday, August 22nd. Barclays raised their target price on shares of Agilent Technologies from $135.00 to $145.00 and gave the stock an “underweight” rating in a report on Tuesday, October 15th. Evercore ISI upped their price target on shares of Agilent Technologies from $135.00 to $145.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. Finally, Wells Fargo & Company started coverage on shares of Agilent Technologies in a research report on Tuesday, August 27th. They set an “overweight” rating and a $157.00 price target for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $144.36.

Insider Activity

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction that occurred on Thursday, August 22nd. The shares were sold at an average price of $145.00, for a total transaction of $283,910.00. Following the sale, the chief executive officer now directly owns 24,118 shares in the company, valued at $3,497,110. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Padraig Mcdonnell sold 1,958 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $145.00, for a total value of $283,910.00. Following the transaction, the chief executive officer now owns 24,118 shares of the company’s stock, valued at $3,497,110. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, SVP Dominique Grau sold 9,990 shares of Agilent Technologies stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $145.00, for a total value of $1,448,550.00. Following the sale, the senior vice president now directly owns 40,011 shares of the company’s stock, valued at $5,801,595. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,995 shares of company stock valued at $1,739,510 in the last 90 days.

Agilent Technologies Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.